Ascendis Pharma A (ASND) Accounts Payables (2012 - 2026)

Ascendis Pharma A (ASND) has 15 years of Accounts Payables data on file, last reported at $92.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 3.67% year-over-year to $92.0 million; the trailing twelve-month figure through Mar 2026 stood at $92.0 million (up 3.67% YoY), and the FY2025 full-year result was $105.5 million, up 1.15% from the prior year.
• Accounts Payables retreated to $92.0 million in Q1 2026, from $105.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $141.1 million in Q1 2023 to a low of $79.3 million in Q1 2022.
• A 5-year average of $102.2 million and a median of $102.7 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables jumped 77.84% in 2023 and plunged 37.53% in 2024, its largest moves.
• Tracing ASND's Accounts Payables over 5 years: stood at $103.1 million in 2022, then dropped by 1.29% to $101.7 million in 2023, then grew by 1.24% to $103.0 million in 2024, then increased by 2.45% to $105.5 million in 2025, then declined by 12.81% to $92.0 million in 2026.
• Business Quant data shows ASND's Accounts Payables at $92.0 million in Q1 2026, $105.5 million in Q4 2025, and $91.9 million in Q3 2025.